Comparing Durvalumab and Pembrolizumab for Biliary Tract Cancer
Author Information
Author(s): Wang Bi-Cheng, Kuang Bo-Hua, Lin Guo-He, Fu Chen
Primary Institution: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Hypothesis
Does combining durvalumab or pembrolizumab with chemotherapy improve survival outcomes in patients with advanced biliary tract cancer?
Conclusion
Durvalumab and pembrolizumab improve survival outcomes for patients with biliary tract cancer, but the overall survival gains are modest.
Supporting Evidence
- The immunotherapy plus chemotherapy group showed superior overall survival compared to the chemotherapy group.
- Durvalumab and pembrolizumab had similar effects on overall survival.
- Gemcitabine maintenance treatment significantly improved overall survival compared to limited cycles.
Takeaway
This study shows that two new cancer drugs, durvalumab and pembrolizumab, can help people with a specific type of cancer live a little longer when used with chemotherapy.
Methodology
Patient-level overall survival and progression-free survival data were reconstructed and analyzed using a one-stage approach from the TOPAZ-1 and KEYNOTE-966 trials.
Potential Biases
Low risk of bias among the enrolled trials, but inherent heterogeneities exist.
Limitations
The analysis is indirect and based on reconstructed patient-level data, which may introduce inherent heterogeneities.
Participant Demographics
Participants included both male and female patients with advanced biliary tract cancer, with a median age of around 64 years.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI 0.74-0.92
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website